Skip to main content
OpenTrials
Completed

NCT Number: NCT01645787

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

The purpose of this study is to assess whether 4-AP (Dalfampridine-ER, Ampyra) improves walking ability and endurance in adult patients with Spinal muscular atrophy (SMA) Type 3 compared to placebo and whether the duration of treatment affects outcome.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Columbia University Medical Center

New York, 10032, United States

About this study

Spinal muscular atrophy (SMA) is a genetically determined neuromuscular disorder that results in muscle weakness and impaired functional mobility. Fatigue is a common symptom in SMA with a resultant impact on physical function and quality of life however the precise mechanisms are unknown. At present there is no treatment for SMA. There is evidence that 4-AP improves function in SMA animal models. In patients with multiple sclerosis, 4-AP was found to improve walking ability and diminish fatigue. The purpose of the study is to determine whether treatment with 4-AP is associated with an increase in walking speed and endurance compared to placebo and whether the duration of treatment affects outcome. The study comprises a short term treatment trial in which participants are treated for 2 weeks with 4-AP and placebo in random sequence followed by a long treatment trial of 6 weeks in which patients are also treated with placebo and 4 AP. The primary outcome measure of the clinical study will be the six minute walk test (6MWT), which has been documented to be a valid and sensitive instrument to identify fatigue among ambulatory SMA patients. We will also assess the effect of 4-AP on muscle and nerve electrical function via electromyography (EMG) during the short term trial. Results of this study may provide support for larger clinical trials.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 to 50 years at the time of enrollment
  • Have genetically confirmed SMA 3 (homozygous absence of SMN1 exon 7)
  • Ability to walk at least 25 meters without assistance
  • Be free of major orthopedic deformities (i.e. scoliosis, contractures)
  • Normal Cystatin C clearance (> 80 ml/min)

Exclusion criteria

  • Patients with a history of seizures
  • Patients with any renal impairment
  • Inability to comply with the study procedures
  • Unstable medical illness
  • Any ventilatory assistance
  • Taking experimental medication for SMA other than under this protocol
  • Pregnancy or lactation
  • Menstruating women, not sterilized or not using effective birth control
  • Planning to undergo scoliosis surgery within the next 10 months
  • Inability to give informed consent

Treatment and study plan

4-aminopyridine

Drug

10 mg/twice daily

Other names: dalfampridine-ER, Ampyra

Placebo

Drug

Crossover study involving one trial with sugar pill (placebo)

Other names: Sugar pill

Primary outcomes

  1. Six Minute Walk Test (6MWT) With Kinematic Evaluation of Gait (Short Term)

    Time frame: Day 14 of each short-term intervention period

    The primary outcome measure will be distance walked in the 6MWT. This measure is an objective evaluation of functional capacity which measures the distance a person can walk quickly in six minutes and is most representative of a person's ability because the test intensity is self-selected. The 6MWT can be safely performed in ambulatory SMA patients and correlates with standard SMA outcome measures including timed walking tests. In SMA, the 6MWT may be more sensitive to clinically meaningful changes in patients with type 3 SMA as it is a direct measure of their functional mobility.

  2. Six Minute Walk Test (6MWT) With Kinematic Evaluation of Gait (Long Term)

    Time frame: Day 42 of each long-term intervention period

    The primary outcome measure will be distance walked in the 6MWT. This measure is an objective evaluation of functional capacity which measures the distance a person can walk quickly in six minutes and is most representative of a person's ability because the test intensity is self-selected. The 6MWT can be safely performed in ambulatory SMA patients and correlates with standard SMA outcome measures including timed walking tests. In SMA, the 6MWT may be more sensitive to clinically meaningful changes in patients with type 3 SMA as it is a direct measure of their functional mobility.

Secondary outcomes

  1. Hammersmith Functional Motor Scale, Expanded (HFMSE) (Short Term)

    Time frame: Day 14 of each short-term intervention period

    Assessments of motor function are clinically relevant and are a good adjunct to tests of walking ability. The HFMSE, a 33-item scale designed for SMA type 2 and 3 patients, and is associated with minimal patient burden requiring only standard equipment and is completed on average in less than 15 minutes. The HFMSE showed good test-retest reliability and is correlated with other clinical and physiological measures in SMA. The score range is 0 (all items failed) to 66 (all items achieved unaided), with higher score indicating higher level of motor function.

  2. Hammersmith Functional Motor Scale, Expanded (HFMSE) (Long Term)

    Time frame: Day 42 of each long-term intervention period

    Assessments of motor function are clinically relevant and are a good adjunct to tests of walking ability. The HFMSE, a 33-item scale designed for SMA type 2 and 3 patients, and is associated with minimal patient burden requiring only standard equipment and is completed on average in less than 15 minutes. The HFMSE showed good test-retest reliability and is correlated with other clinical and physiological measures in SMA. The score range is 0 (all items failed) to 66 (all items achieved unaided), with higher score indicating higher level of motor function.

  3. Manual Muscle Testing (MMT) Total Score (Short Term)

    Time frame: Day 14 of each short-term intervention period

    MMT will involve pushing and pulling against the evaluators hand (MMT). The purpose of this test is to measure the strength in different muscles. MMT was performed on 28 muscle groups (8 muscle groups on each leg and 6 muscle groups on each arm), including proximal and distal musculature. The score range for each muscle group is 0 to 10, with a higher score indicating better muscle strength. The total score range is 0 to 280.

  4. Manual Muscle Testing (MMT) Total Score (Long Term)

    Time frame: Day 42 of each long-term intervention period

    MMT will involve pushing and pulling against the evaluators hand (MMT). The purpose of this test is to measure the strength in different muscles. MMT was performed on 28 muscle groups (8 muscle groups on each leg and 6 muscle groups on each arm), including proximal and distal musculature. The score range for each muscle group is 0 to 10, with a higher score indicating better muscle strength. The total score range is 0 to 280.

  5. Motor Unit Number Estimation (MUNE)

    Time frame: Day 14 of each short-term intervention period

    Motor Unit Number Estimation (MUNE) is a noninvasive test that identifies the number of motor units (motor nerve cells and the territory of muscle fibers they control) using electrical muscle stimulation and recording the response. The nerve conduction study involves the administration of modest electrical stimulations (pulsations or throbbing sensations from low level electricity) to a total of 4 nerves in the right arm and leg while recording the response over a muscle innervated by each nerve. MUNE is calculated by determining the compound motor action potential (CMAP) amplitude or area under the curve of a distal muscle in response to supramaximal stimulation, and then dividing the result by the amplitude or area under the curve of a single motor unit action potential.

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Collaborators

  • United States Department of Defense

Registry information

Official study title

Columbia SMA Project: 4-AP as a Potential SMA Therapeutic Agent and Biological Mechanisms of Action

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Jul 20, 2012
Registry last updated
Sep 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.